Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. George Magrath M.B.A., M.D., M.S. | CEO & Director | 601.25k | -- | 1984 |
| Mr. Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary | 417.56k | -- | 1956 |
| Ms. Amy Zaremba Rabourn C.P.A., MAcc | Senior Vice President of Finance | 417.56k | -- | 1981 |
| Mr. Nirav Suresh Jhaveri C.F.A. | Chief Financial Officer | -- | -- | 1978 |
| Mr. Joseph K. Schachle MBA | Chief Operating Officer | -- | -- | 1965 |
| Dr. Ashwath Jayagopal Ph.D. | Chief Scientific & Development Officer | -- | -- | 1982 |
| Ms. Bindu Manne | Head of Market Development & Commercialization | -- | -- | -- |
| Mr. Erik Sims | Director & Corporate Controller | -- | -- | -- |
Opus Genetics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Corporate Governance
Upcoming Events
March 6, 2025 at 1:30 PM UTC - March 10, 2025 at 1:30 PM UTC
Opus Genetics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available